NR4A3 and chronic myelogenous leukemia, BCR-ABL1 positive: Progressive NR4A3 downregulation was coincident with impairments in differentiation in patients during progression to blastic phase of CML, and NR4A3 expression was increased in APL patients treated with ATRA-based differentiating therapy.